Home › Asset managers › Voya › 2024-2025 › Against the board
At least 6,028 proposals in the 2024-2025 proxy season: Voya voted against, or withheld its votes from, at least 6,000 proposals put forward by company boards, and voted for 28 shareholder proposals, by its own Form N-PX filings.
Two kinds of vote are listed: a board-sponsored proposal Voya voted AGAINST or withheld on, and a shareholder proposal it voted FOR, with the board’s recommendation on it where the filings show one. A FOR vote on a proposal the board supported, or took no position on, is listed and labelled, but it is not a vote against the board. One row is one proposal at one meeting; “funds” is how many of the manager’s funds or accounts voted that way.
Everything Only shareholder proposals it backed
6,028 proposals. The board-sponsored half of this list keeps the 6,000 proposals with the most funds behind them; the rest are in the interactive database. Every shareholder proposal it backed is listed in full.
| Company | Meeting | Proposal | Category | On the ballot from | Board recommended | Voya voted | Funds |
|---|---|---|---|---|---|---|---|
| Bufab AB | April 24, 2025 | Reelect Anna Liljedahl as Director | Director Elections | Board | AGAINST | 1 | |
| Bufab AB | April 24, 2025 | Reelect Bengt Liljedahl as Board Chair | Director Elections | Board | AGAINST | 1 | |
| Bufab AB | April 24, 2025 | Reelect Bengt Liljedahl as Director | Director Elections | Board | AGAINST | 1 | |
| Bufab AB | April 24, 2025 | Reelect Eva Nilsagard as Director | Director Elections | Board | AGAINST | 1 | |
| Buffalo, Inc. | June 25, 2025 | Approve Director Retirement Bonus | Compensation | Board | AGAINST | 1 | |
| Buffalo, Inc. | June 25, 2025 | Elect Director Maki, Hiroyuki | Director Elections | Board | AGAINST | 1 | |
| Buffalo, Inc. | June 25, 2025 | Elect Director and Audit Committee Member Nagase, Yoshimasa | Director Elections | Board | AGAINST | 1 | |
| Build King Holdings Limited | May 21, 2025 | Approve Issuance of Equity or Equity-Linked Securities without Preemptive Rights | Capital Structure | Board | AGAINST | 1 | |
| Build King Holdings Limited | May 21, 2025 | Authorize Reissuance of Repurchased Shares | Capital Structure | Board | AGAINST | 1 | |
| Build King Holdings Limited | May 21, 2025 | Elect Ho Tai Wai, David as Director | Director Elections | Board | AGAINST | 1 | |
| Bunka Shutter Co. Ltd. | June 17, 2025 | Elect Director and Audit Committee Member Uesaka, Motoi | Director Elections | Board | AGAINST | 1 | |
| Burkhalter Holding AG | May 13, 2025 | Approve Variable Remuneration of Executive Committee in the Amount of CHF 1.2 Million | Compensation | Board | AGAINST | 1 | |
| Burkhalter Holding AG | May 13, 2025 | Reappoint Gaudenz Domenig as Member of the Compensation Committee | Director Elections | Board | AGAINST | 1 | |
| Burkhalter Holding AG | May 13, 2025 | Reappoint Michele Novak-Moser as Member of the Compensation Committee | Director Elections | Board | AGAINST | 1 | |
| Burkhalter Holding AG | May 13, 2025 | Reappoint Willy Hueppi as Member of the Compensation Committee | Director Elections | Board | AGAINST | 1 | |
| Burkhalter Holding AG | May 13, 2025 | Reelect Diego Brueesch as Director | Director Elections | Board | AGAINST | 1 | |
| Burkhalter Holding AG | May 13, 2025 | Reelect Gaudenz Domenig as Director and Board Chair | Director Elections | Board | AGAINST | 1 | |
| Burkhalter Holding AG | May 13, 2025 | Reelect Marco Syfrig as Director | Director Elections | Board | AGAINST | 1 | |
| Burkhalter Holding AG | May 13, 2025 | Reelect Michele Novak-Moser as Director | Director Elections | Board | AGAINST | 1 | |
| Burkhalter Holding AG | May 13, 2025 | Reelect Nina Remmers as Director | Director Elections | Board | AGAINST | 1 | |
| Burkhalter Holding AG | May 13, 2025 | Reelect Willy Hueppi as Director | Director Elections | Board | AGAINST | 1 | |
| Business Brain Showa-ota, Inc. | June 23, 2025 | Elect Director and Audit Committee Member Yano, Nahoko | Director Elections | Board | AGAINST | 1 | |
| Buzzi SpA | May 13, 2025 | Approve Remuneration Policy | Compensation | Board | AGAINST | 1 | |
| Buzzi SpA | May 13, 2025 | Authorize Share Repurchase Program and Reissuance of Repurchased Shares | Capital Structure | Board | AGAINST | 1 | |
| Byggmax Group AB | May 6, 2025 | Reelect Anders Moberg (Chair), Daniel Muhlbach, Gunilla Spongh, Lars Ljungalv, Andreas Elgaard and Catarina Fagerholm as Directors; Ratify PricewaterhouseCoopers AB as Auditor | Director Elections | Board | AGAINST | 1 | |
| C&A Modas SA | April 30, 2025 | Elect Directors | Director Elections | Board | AGAINST | 1 | |
| C&A Modas SA | April 30, 2025 | Elect Marcos Guimaraes Grasso as Board Chair | Director Elections | Board | AGAINST | 1 | |
| C&A Modas SA | April 30, 2025 | In Case Cumulative Voting Is Adopted, Do You Wish to Equally Distribute Your Votes Amongst the Nominees below? | Director Elections | Board | ABSTAIN | 1 | |
| C&A Modas SA | April 30, 2025 | Percentage of Votes to Be Assigned - Elect Cristina Presz Palmaka de Luca as Independent Director | Director Elections | Board | ABSTAIN | 1 | |
| C&A Modas SA | April 30, 2025 | Percentage of Votes to Be Assigned - Elect Isabella de Oliveira Vianna Cavalcanti Wanderley as Independent Director | Director Elections | Board | ABSTAIN | 1 | |
| C&A Modas SA | April 30, 2025 | Percentage of Votes to Be Assigned - Elect Jamil Sud Marques as Independent Director | Director Elections | Board | ABSTAIN | 1 | |
| C&A Modas SA | April 30, 2025 | Percentage of Votes to Be Assigned - Elect Marcos Guimaraes Grasso as Director | Director Elections | Board | ABSTAIN | 1 | |
| C&A Modas SA | April 30, 2025 | Percentage of Votes to Be Assigned - Elect Peter Takaharu Furukawa as Independent Director | Director Elections | Board | ABSTAIN | 1 | |
| CCK Consolidated Holdings Berhad | May 28, 2025 | Elect Tiong Chiong Hiiung as Director | Director Elections | Board | AGAINST | 1 | |
| CELSYS, Inc. | March 28, 2025 | Approve Director Retirement Bonus | Compensation | Board | AGAINST | 1 | |
| CELSYS, Inc. | March 28, 2025 | Elect Director and Audit Committee Member Nozaki, Shinya | Director Elections | Board | AGAINST | 1 | |
| CIR SpA - Cie Industriali Riunite | April 28, 2025 | Approve 2025 Stock Grant Plan | Compensation | Board | AGAINST | 1 | |
| CIR SpA - Cie Industriali Riunite | April 28, 2025 | Approve Capital Increase and Convertible Bond Issuance with or without Preemptive Rights | Capital Structure | Board | AGAINST | 1 | |
| CIR SpA - Cie Industriali Riunite | April 28, 2025 | Approve Remuneration Policy | Compensation | Board | AGAINST | 1 | |
| CIR SpA - Cie Industriali Riunite | April 28, 2025 | Approve Second Section of the Remuneration Report | Compensation | Board | AGAINST | 1 | |
| CIR SpA - Cie Industriali Riunite | April 28, 2025 | Authorize Share Repurchase Program and Reissuance of Repurchased Shares | Capital Structure | Board | AGAINST | 1 | |
| CITIC Limited | June 25, 2025 | Approve Issuance of Equity or Equity-Linked Securities without Preemptive Rights | Capital Structure | Board | AGAINST | 1 | |
| CITIC Limited | June 25, 2025 | Elect Gregory Lynn Curl as Director | Director Elections | Board | AGAINST | 1 | |
| CITIC Limited | June 25, 2025 | Elect Li Zimin as Director | Director Elections | Board | AGAINST | 1 | |
| CITIC Limited | June 25, 2025 | Elect Xi Guohua as Director | Director Elections | Board | AGAINST | 1 | |
| CITIC Limited | June 25, 2025 | Elect Yang Xiaoping as Director | Director Elections | Board | AGAINST | 1 | |
| CITIC Limited | June 25, 2025 | Elect Yu Yang as Director | Director Elections | Board | AGAINST | 1 | |
| CITIC Limited | June 25, 2025 | Elect Zhang Lin as Director | Director Elections | Board | AGAINST | 1 | |
| CITIC Limited | June 25, 2025 | Elect Zhang Wenwu as Director | Director Elections | Board | AGAINST | 1 | |
| CLIO Cosmetics Co., Ltd. | March 28, 2025 | Elect Han Hyeon-ock as Inside Director | Director Elections | Board | AGAINST | 1 | |
| CLIO Cosmetics Co., Ltd. | March 28, 2025 | Elect Oh Young-ae as Inside Director | Director Elections | Board | AGAINST | 1 | |
| CNOOC Energy Technology & Services Ltd. | June 9, 2025 | Approve External Guarantee Plan and Application of Credit Lines | Capital Structure | Board | AGAINST | 1 | |
| CRA International, Inc. | July 18, 2024 | To approve, on an advisory basis, the compensation paid to CRA's named executive officers, as disclosed in the proxy statement for the 2024 meeting of its shareholders. | Say-on-Pay | Board (inferred) | AGAINST | 1 | |
| CREEK & RIVER Co., Ltd. | May 29, 2025 | Elect Director Sawada, Hideo | Director Elections | Board | AGAINST | 1 | |
| CSC Steel Holdings Bhd. | May 29, 2025 | Approve Lim Lay Ching to Continue Office as Independent Non-Executive Director | Director Elections | Board | AGAINST | 1 | |
| CSC Steel Holdings Bhd. | May 29, 2025 | Elect Chen, Wei-Tei (Chen, Victor) as Director | Director Elections | Board | AGAINST | 1 | |
| CSC Steel Holdings Bhd. | May 29, 2025 | Elect Cho, Chun-Yi as Director | Director Elections | Board | AGAINST | 1 | |
| CSC Steel Holdings Bhd. | May 29, 2025 | Elect Huang, Ching-Huei as Director | Director Elections | Board | AGAINST | 1 | |
| CSC Steel Holdings Bhd. | May 29, 2025 | Elect Lim Lay Ching as Director | Director Elections | Board | AGAINST | 1 | |
| CSE Global Limited | April 21, 2025 | Approve Issuance of Equity or Equity-Linked Securities with or without Preemptive Rights | Capital Structure | Board | AGAINST | 1 | |
| CSE Global Limited | April 21, 2025 | Elect Tan Chian Khong as Director | Director Elections | Board | AGAINST | 1 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Attribution of Profit and Loss During the Transition Period | Extraordinary Transactions | Board | AGAINST | 1 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Audit Report, Pro Forma Review Report and Valuation Report in Relation to the Transaction | Extraordinary Transactions | Board | AGAINST | 1 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Authorization of the Board and Its Authorized Persons to Handle All Related Matters | Extraordinary Transactions | Board | AGAINST | 1 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Completeness and Compliance of Implementation of Legal Proceedings of the Transaction and Validity of the Submitted Legal Documents | Extraordinary Transactions | Board | AGAINST | 1 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Confidentiality Measures and Confidentiality System Adopted for This Transaction | Extraordinary Transactions | Board | AGAINST | 1 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Description of the Basis and Fairness and Reasonableness of the Pricing of the Transaction | Extraordinary Transactions | Board | AGAINST | 1 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Distribution Arrangement of Undistributed Earnings | Extraordinary Transactions | Board | AGAINST | 1 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Fluctuation of the Company's Stock Price Before the Release of Information on This Transaction | Extraordinary Transactions | Board | AGAINST | 1 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Impact of Dilution of Current Returns on Major Financial Indicators, the Relevant Measures to be Taken and Commitment from Relevant Parties | Extraordinary Transactions | Board | AGAINST | 1 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Independence of Appraiser, the Validity of Hypothesis, the Relevance of Valuation Method and Purpose and Approach as Well as the Fairness of Pricing | Extraordinary Transactions | Board | AGAINST | 1 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Issue Amount | Extraordinary Transactions | Board | AGAINST | 1 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Issue Amount and Number of Issues | Extraordinary Transactions | Board | AGAINST | 1 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Issue Manner and Target Subscribers | Extraordinary Transactions | Board | AGAINST | 1 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Issue Type, Par Value and Listing Location | Extraordinary Transactions | Board | AGAINST | 1 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Lock-Up Period Arrangement | Extraordinary Transactions | Board | AGAINST | 1 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Overall Plan | Extraordinary Transactions | Board | AGAINST | 1 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Performance Commitment and Compensation Arrangement | Extraordinary Transactions | Board | AGAINST | 1 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Pricing Reference Date and Issue Price | Extraordinary Transactions | Board | AGAINST | 1 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Purchases and Sales of Assets in the Twelve Months Prior to the Transaction | Extraordinary Transactions | Board | AGAINST | 1 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Report (Draft) and Summary on Issuance of Shares and Acquisition by Cash as Well as Raising Supporting Funds and Related Party Transactions | Extraordinary Transactions | Board | AGAINST | 1 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Report on the Usage of Previously Raised Funds | Capital Structure | Board | AGAINST | 1 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Resolution Validity Period | Extraordinary Transactions | Board | AGAINST | 1 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Signing of Conditional Agreement to the Issuance of Shares and Acquisition by Cash as well as Performance Compensation Agreement | Extraordinary Transactions | Board | AGAINST | 1 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Target Assets | Extraordinary Transactions | Board | AGAINST | 1 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Transaction Complies With Article 18 and 21 of the Measures for the Continuous Supervision of ChiNext Listed Companies (Trial) and Article 8 of the Shenzhen Stock Exchange Listed Company Major Asset Restructuring Review Rules | Extraordinary Transactions | Board | AGAINST | 1 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Transaction Complies With Article 4 of Guidelines for the Supervision of Listed Companies No. 9 - Regulatory Requirements for Listed Companies to Plan and Implement Major Asset Restructuring | Extraordinary Transactions | Board | AGAINST | 1 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Transaction Complies with Articles 11 and 43 of the Measures for the Administration of Major Asset Restructuring of Listed Companies | Extraordinary Transactions | Board | AGAINST | 1 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Transaction Complies with the Relevant Provisions of the Administrative Measures for the Registration of Securities Issuance of Listed Companies | Extraordinary Transactions | Board | AGAINST | 1 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Transaction Constitute as Major Asset Restructuring and Does Not Constitute as Restructuring and Listing | Extraordinary Transactions | Board | AGAINST | 1 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Transaction Parties | Extraordinary Transactions | Board | AGAINST | 1 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Transaction Price and Payment Method | Extraordinary Transactions | Board | AGAINST | 1 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve Use of Proceeds | Capital Structure | Board | AGAINST | 1 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve the Company's Plan for Issuance of Shares and Acquisition by Cash as Well as Raising Supporting Funds Complies with Relevant Laws and Regulations | Extraordinary Transactions | Board | AGAINST | 1 | |
| CSPC Innovation Pharmaceutical Co., Ltd. | October 31, 2024 | Approve the Relevant Entity of Transaction Does Not Exist in Article 12 of Listed Company Supervision Guidelines No. 7 and Article 30 of the Guidelines for Self-regulatory Supervision No. 8 (Revised in 2023) | Extraordinary Transactions | Board | AGAINST | 1 | |
| CTS Co., Ltd. | June 20, 2025 | Elect Director and Audit Committee Member Hirano, Seiichi | Director Elections | Board | AGAINST | 1 | |
| CTS Co., Ltd. | June 20, 2025 | Elect Director and Audit Committee Member Yokoyama, Takashi | Director Elections | Board | AGAINST | 1 | |
| Cabaletta Bio, Inc. | June 9, 2025 | To elect two class III directors to our board of directors, to serve until the 2028 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: Steven Nichtberger, M.D. | Director Elections | Board | WITHHOLD | 1 | |
| Caesarstone Ltd. | September 19, 2024 | Reelect Ariel Halperin as Director | Director Elections | Board | AGAINST | 1 | |
| Cairo Communication SpA | March 25, 2025 | Authorize Purchase of Own Shares also via Voluntary Partial Tender Offer and Disposal of Own Shares | Extraordinary Transactions | Board | AGAINST | 1 |
← Previous Page 57 of 61 Next →
← Back to Voya 2024-2025 overview
Built November 8, 2026 from SEC Form N-PX filings.